New Whitepaper 

Pharma R&D Annual Review 2020

What’s Inside:

The disease focus areas of the top 10 pharma companies

Where in the world R&D is actually occurring

Which company saw the biggest decline in pipeline size

The number of new drug protein targets identified by year

Which big pharma company exhibits the most intense single therapeutic focus

All Rights Reserved. Forward ® 2020

EBD Group Inc., 3150 Pio Pico Drive, Suite 201, Carlsbad, CA 92008

While travel and face-to-face interaction may not be safe or even possible, biotech, pharma, and financial attendees can still access the unparalleled partnering and content offered by ChinaBio® Partnering Forum, BioPharm America™ and BIO-Europe® in August, September and October, either as individual conferences, or with a Virtual Passport to all three, at a substantially reduced fee.


 Global Partnering Events 

Delivered Digitally 

Discover where R&D is heading as we move into an exciting new decade!

In this new whitepaper, Pharma Intelligence takes a deep dive into the data and assesses industry trends by examining pharmaceutical pipelines by company, therapeutic area, disease, target and drug type.

Brought to you by: